Identifying dopamine supersensitivity through a randomized controlled study of switching to aripiprazole from other antipsychotic agents in patients with schizophrenia.

"Conflict of interest statement: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr. Tzung-Jeng Hwang has received a research grant from AstraZeneca and honoraria from AstraZeneca, Taiwan Otsuka Pharmaceutical Co., and Eli Lilly and Company. Drs. Chia-Hao Ma, Hung-Yu Chan, Ming H. Hsieh, Chen-Chun Liu, Chih-Min Liu, Hai-Gwo Hwu, Ching-Hua Kuo, and Wei J. Chen report no other financial disclosures relevant to the subject of this article."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by grants from the National Science Council, Taiwan (NSC 96-2628-B-002-066-MY2; NSC98-2314-B-002-125-MY3), and National Clinical Trial and Research Center at National Taiwan University Hospital (NCTRC200724)."

"Trial Registration: ClinicalTrials.gov, identifier: NCT00545467"